Alnylam Pharmaceuticals Inc (ALNY)
Alnylam Pharmaceuticals: The RNAi Leader Continues To Grind Through A Quieter Year
Alnylam Pharmaceuticals remains well-positioned in the TTR amyloidosis market, with a robust franchise and reliable clinical asset generation. Q1 2026 results showed 150% year-over-year TTR franchise growth despite insurance and pricing headwinds; Amvuttra continues to gain front-line share. ALNY maintains full-year TTR revenue guidance of $4.4B–$4.7B, with ongoing investments in earlier diagnosis and care coordination to expand the addressable market.
Alnylam (ALNY) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Alnylam (ALNY) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Alnylam Pharmaceuticals (ALNY) Tops Q1 Earnings and Revenue Estimates
Alnylam Pharmaceuticals (ALNY) came out with quarterly earnings of $1.99 per share, beating the Zacks Consensus Estimate of $1.43 per share. This compares to a loss of $0.01 per share a year ago.
Alnylam (ALNY) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
Beyond analysts' top-and-bottom-line estimates for Alnylam (ALNY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2026.
Why Alnylam (ALNY) is Poised to Beat Earnings Estimates Again
Alnylam (ALNY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Alnylam Pharmaceuticals (ALNY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in Alnylam Pharmaceuticals Stock?
Investors need to pay close attention to ALNY stock based on the movements in the options market lately.
5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up
Oncology M&A activity is accelerating as large pharmaceutical companies race to replenish pipelines facing patent cliffs and seek exposure to next-generation therapeutic platforms.
Alnylam Pharmaceuticals, Inc. (ALNY) Discusses Progress and Strategy in Transforming ATTR Amyloidosis Care and Expanding TTR Franchise Transcript
Alnylam Pharmaceuticals, Inc. (ALNY) Discusses Progress and Strategy in Transforming ATTR Amyloidosis Care and Expanding TTR Franchise Transcript
Can Alnylam's Pipeline Drugs Sustain Long-Term Growth Ahead?
ALNY's strong drug sales and advancing pipeline, including late-stage candidates, are driving momentum and supporting its long-term growth outlook.
Alnylam Pharmaceuticals, Inc. $ALNY Shares Bought by Anchor Investment Management LLC
Anchor Investment Management LLC grew its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 1,024.5% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,249 shares of the biopharmaceutical company's stock after acquiring an additional 2,049 shares during the period.
How Alnylam Stock Weathers Market Shocks
Investing in equities involves accepting volatility as the cost of long-term compounding. In 15 significant systemic shocks during which Alnylam Pharmaceuticals (ALNY) was traded, the stock experienced an average drawdown of -25%.
